News

Novartis Set to Acquire Anthos Therapeutics in Major Deal

Novartis Set to Acquire Anthos Therapeutics in Major Deal

Novartis and Anthos Therapeutics: A Groundbreaking Acquisition

Blackstone Life Sciences and Anthos Therapeutics, Inc. are excited to announce a monumental agreement in the biopharmaceutical sector. Anthos Therapeutics, a transformative clinical-stage company specializing in innovative therapies for cardiometabolic diseases, has reached an agreement with Novartis to be acquired for up to $3.1 billion. Founded in 2019 by Blackstone Life Sciences and Novartis, Anthos has developed a promising drug candidate—abelacimab, a pioneering factor XI inhibitor.

Unveiling Abelacimab's Potential

Abelacimab is designed to prevent stroke and systemic embolism in patients suffering from atrial fibrillation while also addressing blood clot recurrence in cancer patients. This innovative treatment is a significant leap towards combating these widespread medical issues. Bill Meury, Chief Executive Officer at Anthos, expressed his enthusiasm regarding abelacimab's potential, stating that it could become a vital option for the millions at risk of stroke globally. Meury highlighted the strength of Novartis in driving this development, appreciative of the past efforts from everyone involved over the years.

Growth and Development since Inception

Dr. Nicholas Galakatos, Chairman of Anthos’ Board of Directors, shared pride in the journey since Anthos was established. The team successfully acquired the rights to abelacimab and assembled a world-class team to spearhead developmental efforts. Galakatos emphasizes the importance of Novartis as a partner in advancing abelacimab's potential, noting that this collaboration exemplifies Blackstone Life Sciences' sound investment strategy focused on nurturing innovative products that meet patient needs.

Clinical Studies Indicate Efficacy

In clinical studies, abelacimab has demonstrated significant advantages over existing treatments such as rivaroxaban (Xarelto), including a marked reduction in major bleeding incidents. The Independent Data Monitoring Committee's decision to conclude the study early underscored the drug's promising results, indicating a bright future ahead for this novel treatment option. Furthermore, Anthos is actively conducting several phase 3 studies, including LILAC-TIMI 76 for atrial fibrillation patients and ASTER and MAGNOLIA focusing on cancer-associated thrombosis. Results from these studies could provide valuable data by the second half of 2026.

Transaction Overview and What Lies Ahead

The acquisition entails an initial payment of $925 million to Anthos shareholders upon closing. Additional payments tied to regulatory and commercial milestones may follow. The transaction is anticipated to close in the first half of 2025, pending regulatory approvals and the satisfaction of customary conditions. This merger signals an exciting new chapter for both Anthos and Novartis, indicating their commitment to innovation in healthcare.

Industry Leadership and Future Aspirations

Blackstone Life Sciences has established itself as an industry leader through its strategic investments in transformative companies like Anthos. Currently holding over $12 billion in assets under management, Blackstone is well-positioned to drive significant advances in the biopharmaceutical landscape. By harnessing their operational expertise and resources, they aim to launch groundbreaking medical solutions that can markedly boost patient care.

What is Abelacimab?

Abelacimab is a unique investigational monoclonal antibody that effectively inhibits Factor XI, aiming to alleviate thromboembolic diseases by mimicking natural Factor XI deficiency’s protective benefits. This innovative therapy has already received Fast Track Designations from the FDA, reflecting its promise in treating cancer-associated thrombosis and preventing strokes related to atrial fibrillation.

Frequently Asked Questions

What is the significance of the agreement between Novartis and Anthos?

The agreement signifies a major step forward in developing abelacimab as a vital treatment for stroke and thrombosis, expanding the pipeline of innovative therapies in cardiometabolic diseases.

What is the expected timeline for the acquisition's completion?

The transaction is expected to finalize in the first half of 2025, pending necessary regulatory approvals and conditions.

What are the key features of abelacimab?

Abelacimab is a highly selective monoclonal antibody that targets Factor XI, aimed at preventing stroke and addressing recurrent blood clots in cancer patients.

How has abelacimab performed in clinical trials?

Clinical trials have shown promising results for abelacimab, including significant reductions in bleeding complications compared to traditional treatments.

Who are the advisors involved in this acquisition?

Goldman Sachs & Co. LLC is the lead financial advisor, alongside Morgan Stanley & Co. LLC and Goodwin Procter LLP, serving as legal advisor to Anthos.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 49

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 618

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 52

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

UROVO Launches Innovative Products to Transform Retail and Warehousing

Updated Category News Views 415

UROVO Launches Innovative Products to Transform Retail and Warehousing At EuroCIS 2025, UROVO, a leading name in industry applications, has unveiled four cutting-edge products: the UHF RFID Sled RFG91, Lightweight UHF RFID Handheld Reader DT50P Lite, Wireless Barcode Scanner K180, and Wearable Computer U2S. These innovations are set to revolutionize retail and warehouse...

Continue Reading
Ameren Corporation Launches New Stock Offering Initiative

Updated Category News Views 331

Ameren Corporation Unveils New Stock Offering In a strategic move to bolster its financial position, Ameren Corporation (NYSE: AEE) has announced the pricing of a significant underwritten offering of common stock. The company is set to offer 5,550,416 shares at an attractive public price of $94.00 each. This offering is aimed at facilitating various corporate financial...

Continue Reading
Exciting Developments: 2025 Bank of America Chicago Marathon

Updated Category News Views 224

Discover the 2025 Bank of America Chicago Marathon Lineup Chicago is gearing up for a thrilling marathon experience as the Bank of America Chicago Marathon announces its professional field for the upcoming event. Scheduled for 2025, the marathon promises to attract some of the world’s most elite runners, including notable champions from previous years. Elite Men Runners...

Continue Reading
Exploring Opportunities and Innovations at ASI Show 2025

Updated Category News Views 157

ASI Show 2025 Unveils Trends and Insights in Promotional Products The Advertising Specialty Institute just wrapped up an exciting event, showcasing the latest in promotional products and networking at the ASI Show 2025 in Fort Worth. Distributors and suppliers gathered from around the globe, eager to engage in meaningful discussions amidst challenges faced by the...

Continue Reading
Canada Nickel's Remarkable Nickel Mineralization Discovery

Updated Category News Views 139

Canada Nickel Announces Significant Exploration Results Canada Nickel Company Inc. (TSXV: CNC) is thrilled to share the latest updates from its exploration efforts at the Reid Nickel Sulphide Project. This recent phase of drilling has uncovered astonishing intervals of nickel mineralization, marking a pivotal moment for this promising mining venture. The discoveries are...

Continue Reading